Physician profile
Bindu E Rajan
NPI 1245287093
$16,140.81
in general payments reported to CMS, 2019-2025
72 companies · $2,446 in 2025
The $2,446 reported for 2025 was more than what 95% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,357 · 2020: $1,491 · 2021: $2,221 · 2022: $2,339 · 2023: $2,348 · 2024: $2,937 · 2025: $2,446.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,062 · Consulting Fee: $400 · Education: $269.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,062.39 |
| Consulting Fee | $400.00 |
| Education | $269.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,003.05 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Novo Nordisk INC | $1,583.56 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $1,384.96 | 2019-2025 | Evenity, Repatha, Prolia |
| Abbvie INC. | $1,245.98 | 2019-2025 | |
| Pfizer INC. | $1,087.93 | 2020-2025 | |
| Sanofi-Aventis U.S. LLC | $891.51 | 2019-2023 | |
| Glaxosmithkline, LLC. | $650.94 | 2019-2025 | Shingrix, Trelegy Ellipta, Bexsero |
| Lilly USA, LLC | $592.92 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $549.21 | 2022-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $444.81 | 2019-2025 | Xifaxan, Trulance |
| Teva Pharmaceuticals USA, INC. | $419.42 | 2020-2025 | Ajovy, Austedo Xr, Austedo |
| Astellas Pharma US INC | $391.46 | 2020-2025 | Veozah |
| Radius Health, INC. | $380.06 | 2019-2025 | Tymlos |
| Boehringer Ingelheim Pharmaceuticals, INC. | $355.64 | 2019-2025 | Jardiance, Tradjenta |
| Edwards Lifesciences Corporation | $331.51 | 2022-2025 | Sapien 3 Ultra Resilia, Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
Show all 72 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bindu Rajan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.